Rhythm Pharmaceuticals (RYTM) announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. Popovits previously served as Chairman of the Board, Chief Executive Officer and President of Genomic Health
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Gains EMA Backing for IMCIVREE Expansion
- Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright
- Rhythm Pharmaceuticals selects Pantherx Rare as pharmacy for Imcivree
- Rhythm Wins FDA Nod for Hypothalamic Obesity Therapy
- Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA